Background: Breast cancer survivors who are on adjunct therapy with Aromatase Inhibitors (AIs) or premature menopause due to chemotherapy are known to have an increased risk of osteoporosis. Being at high risk for osteoporosis, these patients should be screened using with dual energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) according to national guidelines. This study screened the population of patients with early Breast cancer utilizing the Arm-DXA as a user friendly and efficient method. Methods: All Breast cancer patients at the Tolna County Cancer Center, Szekszárd who are with diagnosis of early invasive breast cancer were scanned using Arm-DXA during their regular visit to the center. Patients who have metastatic disease or known to have osteoporosis were excluded from the study. Results: During the first six month of the study an arm-DXA scan for BMD was done on 262 patients. Of these 20.6% (n = 54) were postmenopausal and had osteoporosis, in about 34.7% (n = 91) had osteopenia and of those with osteopenia a 79.1% (n: 72) were postmenopausal. Patients who had osteoporosis (with -2.5 T Score or less) were sent to Rheumatology centers. Patients who had osteopenia with T score between -1.5 and -2.5 (n: 54) were sent to all body DXA. The study finds that 26% (n: 69) patients are under adjunct AIs therapy and have clinically significant bone loss. About 43.4% (n: 30) had more than 2 years treatment and were switched to tamoxifen. Conclusions: This study highlights the fact that osteoporosis is an under-detected in early breast cancer survivors who are on or after hormone and chemotherapy. About 55% of early breast cancer survivors found to have osteoporosis or osteopenia in our study. The Arm-DXA as a tool for screening and monitoring can be used in daily practice as user friendly and efficient tool to decrease the gap between the guidelines and real practice on prevention and treatment of osteoporosis in this population.